NASDAQ:IKNA
Ikena Oncology, Inc. Stock News
$1.38
-0.0200 (-1.43%)
At Close: May 21, 2024
Recent Price Trend in Ikena Oncology, Inc. (IKNA) is Your Friend, Here's Why
10:16am, Tuesday, 20'th Jun 2023
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Ikena Oncology, Inc. (IKNA) Is a Great Choice for 'Trend' Investors, Here's Why
09:53am, Friday, 02'nd Jun 2023
Ikena Oncology, Inc. (IKNA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it
Ikena Oncology to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 24'th May 2023
BOSTON, May 24, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
10:41am, Monday, 15'th May 2023
Ikena Oncology, Inc. (IKNA) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.46. This compares to loss of $0.47 per share a year ago.
Ikena Oncology, Inc. (IKNA) Stock Jumps 7.9%: Will It Continue to Soar?
03:50am, Friday, 05'th May 2023
Ikena Oncology, Inc. (IKNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength
Ikena Oncology, Inc. (IKNA) Reports Q4 Loss, Tops Revenue Estimates
09:58am, Tuesday, 14'th Mar 2023
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 26.42% and 67.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock
Ikena Oncology, Inc. (IKNA) Reports Q3 Loss, Tops Revenue Estimates
11:30am, Monday, 07'th Nov 2022
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of 4% and 67.02%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BOSTON, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
Ikena Oncology to Participate in Spring 2022 Investor Conferences
07:00am, Wednesday, 18'th May 2022
BOSTON, May 18, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that
Ikena Oncology, Inc. (IKNA) Reports Q1 Loss, Tops Revenue Estimates
09:47am, Thursday, 12'th May 2022
Ikena Oncology, Inc. (IKNA) delivered earnings and revenue surprises of -11.90% and 4.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Surprise Coming for Ikena Oncology (IKNA) This Earnings Season?
09:47am, Wednesday, 11'th May 2022
Ikena Oncology (IKNA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
5 Biotech Stocks Set to Outpace Q1 Earnings Estimates
09:02am, Wednesday, 11'th May 2022
Let us take a look at some drug/biotech stocks, ANGN, APLT, BOLT, IKNA and LABP, which are poised to beat on first-quarter earnings.
Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
07:00am, Thursday, 28'th Apr 2022
BOSTON, April 28, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced tha
BOSTON, March 07, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that it will
Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference
12:00pm, Tuesday, 01'st Mar 2022 GlobeNewswire
BOSTON, March 01, 2022 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company navigating new territory in patient-directed cancer treatment, today announced that management will be participating in the Targeted Oncology Panel at the Cowen & Co 42 nd Annual Health Care Conference, taking place March 7-9, 2022. The Company will also be holding investor meetings at the conference.